Dynamic Area Telethermometry (DAT) as an Imaging Modality in Patients With Cancer

Not Applicable

Completed

• Conditions: Malignant Tumors; Subcutaneous Tumors; Lymph Node Tumors

• Registration Number: NCT00165100
• Lead Sponsor: Dana-Farber Cancer Institute

Brief Summary

The purpose of this study is to evaluate whether this new method of taking pictures called Dynamic Area Telethermometry (DAT) might be a good way of looking at patients with cancer that is relatively close to the surface of the body.

Detailed Description

* The DAT system resembles a video camera which picks up changes in body temperature which may reflect disease-related changes in blood flow to some areas, particularly those involved with tumors.

* Patients with known tumor sites amendable to DAT evaluation will be imaged at the time of staging and at later time points. Thermal profiles will be compared to those of normal adjacent tissues and correlated with the images of the tumors on conventional images.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2000-01
• Primary Completion: 2002-10
• Study Completion: 2002-10
• Study First Submitted: 2005-09-09
• Study First Submitted QC: 2005-09-09
• Study First Posted: 2005-09-14
• Status Verified: 2007-12
• Last Update Submitted: 2007-12-20
• Last Update Posted: 2007-12-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• Histologically confirmed malignancy
• Primary or secondary tumor location amendable to DAT scanning: subcutaneous tissues
• Older than 15 years of age
• Able to withhold movement for 20 seconds, hold breath for 20 seconds for chest wall lesions and clinically stable acutely

Read More

Exclusion Criteria

• Uncontrolled motion
• Tumors not verified or measurable by standard imaging

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
To assess the feasibility of DAT in tumors detected by conventional imaging and evaluation of therapy induced changes in DAT imaging profile over time.

Trial Locations

Locations (1)

Dana-Farber Cancer Institute; 🇺🇸 Boston, Massachusetts, United States